HomeNewsBusinessEconomyInterview | India needs temporary income support plan, H2 rate hike likely says Nomura's Sonal Varma

Interview | India needs temporary income support plan, H2 rate hike likely says Nomura's Sonal Varma

Nomura’s economist expects the Indian economy to contract 4 percent in April-June compared with Jan-March and that inflation would remain a big risk that may require a hike in reverse-repo rates in the second half of the fiscal

June 16, 2021 / 19:39 IST
Story continues below Advertisement
Illustration by Suneesh Kalarickal
Illustration by Suneesh Kalarickal

India needs a twofold strategy to revive the economy, focusing on productive investments and a temporary income support scheme for the poor, Sonal Varma, chief economist, India and Asia (ex-Japan) at Nomura said.

In an interview with Moneycontrol, Varma said she expected the April-June gross domestic product to contract by about 4 per cent compared with January-March quarter, and that inflationary pressures are expected to remain this year.

Story continues below Advertisement

She said Nomura had raised its inflation projections for FY22 by one percentage point and is looking at close to 6 percent on headline inflation and core CPI between 6-6.5 percent. The Monetary Policy Committee needs to shift focus from growth to inflation, and a reverse-repo rate hike is possible in the second half of this fiscal, she added.

Nomura expects half of India’s population to be fully vaccinated by December 2021, but to get there, the country needs to accelerate inoculation, which is important as it would drive monetary policy, fiscal policy and the economic outlook, she said.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show